Coralia Muino

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Prevalence and clinical outcomes associated with proximal deep vein thrombosis at hospital admission detected by bedside ultrasound in patients hospitalized in a medical oncology ward: An exploratory prospective study.

Prevalence and clinical outcomes associated with proximal deep vein thrombosis at hospital admission detected by bedside ultrasound in patients hospitalized in a medical oncology ward: An exploratory prospective study.

Journal: Thrombosis research
Published: April 21, 2026

Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.

Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.

Journal: Journal of the National Cancer Institute
Published: March 11, 2025

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.

Journal: The Lancet. Oncology
Published: February 13, 2025

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 20, 2024

HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.

HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.

Journal: ESMO open
Published: June 13, 2024

Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.

Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.

Journal: Breast cancer research and treatment
Published: March 01, 2024

Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.

Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.

Journal: JAMA oncology
Published: April 27, 2023

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 19, 2023

Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.

Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.

Journal: Breast cancer research and treatment
Published: January 25, 2023

A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis.

A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis.

Journal: European journal of case reports in internal medicine
Published: October 22, 2022

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.

Journal: Therapeutic advances in medical oncology
Published: June 09, 2022

HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping.

HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping.

Journal: Cancers
Published: November 29, 2021
Showing 1-12 of 15

Last Updated: 09/26/2026